Spain Pharmaceutical Market Overview:
The Spain Pharmaceutical market is projected to exhibit a growth rate (CAGR) of 5.40% during 2024-2032. The market is expanding due to the growing aging population, increasing investment in R&D, generic drugs adoption, and expansion of biopharmaceuticals.
Report Attribute
|
Key Statistics
|
Base Year
|
2023 |
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Growth Rate (2024-2032) |
5.40% |
Spain Pharmaceutical Market Trends:
Growing Aging Population
As people are aging, they are more likely to develop chronic conditions and age-related diseases, such as cardiovascular disease, diabetes, arthritis, and neurodegenerative disorders. The high number of people with these conditions in the aging population underlines the need for pharmaceuticals to treat symptoms, delay progression, and enhance quality of life. Additionally, with an increasing aging population, there is a need to focus on geriatric medicine in Spain. Many pharmaceutical companies are developing tailor drugs as per the specific needs of older adults like formulation that are easier to swallow, produce fewer side effects, and account for age-related changes in the kidney or liver. Furthermore, there is a growing knowledge about the importance of prevention in healthy aging and age-related diseases. Pharmaceutical companies also invest in research and production of preventive drugs and vaccine that reduces the risk of chronic condition such as osteoporosis, dementia and cancers. According to the National Statistics Institute report of 2023, the Spain’s 65 or over to the population aged between 15 and 64 is expected to increase to 35.1% in 2030.
Rising Investments in Research and Development (R&D)
As per the Spanish Institute for Foreign Trade (ICEX), Pharmaceutical companies reached a record of around 1.4 billion R&D investment in Spain in 2023, which was 10% higher from previous year. Increasing R&D investments is leading to the development of innovative pharmaceutical products, such as novel drugs, biologics, vaccines, and medical devices. These innovations meet existing health challenges, enhance the quality of treatment, and advance the field of medicine. In Spain, pharmaceutical companies collaborate with research institutions as well as with biotech companies for R&D and innovation. Furthermore, investments in R&D are contributing to the employment of research scientists, clinical trial coordinators, regulatory affairs professionals and manufacturing technicians in the pharmaceutical sector. R&D activities are catalyzing the demand for goods and services from the related industries, thereby promoting employment and economic development in Spain. In line with this, R&D investments facilitate technology transfer and knowledge exchange between academia, industry, and government agencies in Spain. Collaborative R&D projects enable the transfer of scientific discoveries from academic research laboratories to commercial applications, leading to the development of new therapies and medical technologies.
Spain Pharmaceutical Market News:
- January 16, 2024: Roche announced that the European Commission has granted marketing authorization for Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types.
- February 5, 2024: Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. This acquisition will further expand and complements Novartis pipeline in oncology.
Spain Pharmaceutical Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on type and nature.
Type Insights:
- Pharmaceutical Drugs
- Cardiovascular Drugs
- Dermatology Drugs
- Gastrointestinal Drugs
- Genito-Urinary Drugs
- Hematology Drugs
- Anti-Infective Drugs
- Metabolic Disorder Drugs
- Musculoskeletal Disorder Drugs
- Central Nervous System Drugs
- Oncology Drugs
- Ophthalmology Drugs
- Respiratory Diseases Drugs
- Biologics
- Monoclonal Antibodies (MAbS)
- Therapeutic Proteins
- Vaccines
A detailed breakup and analysis of the market based on the type have also been provided in the report. This includes pharmaceutical drugs (cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorder drugs, musculoskeletal disorder drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs) and biologics (monoclonal antibodies (MAbS), therapeutic proteins, and vaccines).
Nature Insights:
A detailed breakup and analysis of the market based on the nature have also been provided in the report. This includes organic and conventional.
Regional Insights:
- Northern Spain
- Eastern Spain
- Southern Spain
- Central Spain
The report has also provided a comprehensive analysis of all the major regional markets, which include Northern Spain, Eastern Spain, Southern Spain, and Central Spain.
Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Spain Pharmaceutical Market Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
xx |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Types Covered |
- Pharmaceutical Drugs: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs
- Biologics: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines
|
Natures Covered |
Organic, Conventional |
Regions Covered |
Northern Spain, Eastern Spain, Southern Spain, Central Spain |
Customization Scope |
10% Free Customization |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the Spain pharmaceutical market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the Spain pharmaceutical market?
- What is the breakup of the Spain pharmaceutical market on the basis of type?
- What is the breakup of the Spain pharmaceutical market on the basis of nature?
- What are the various stages in the value chain of the Spain pharmaceutical market?
- What are the key driving factors and challenges in the Spain pharmaceutical?
- What is the structure of the Spain pharmaceutical market and who are the key players?
- What is the degree of competition in the Spain pharmaceutical market?
Key Benefits for Stakeholders:
- IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Spain pharmaceutical market from 2018-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the Spain pharmaceutical market.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Spain pharmaceutical industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.